COMPOUND PROFILE / SMALL MOLECULES
CT-996.
Research draftCT-996 is an experimental oral non-peptide GLP-1 receptor agonist.
Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.
Targeted source and identity review, not a systematic review or complete regulatory audit.
Overview
CT-996 is an experimental oral non-peptide GLP-1 receptor agonist.
Mechanism
It targets GLP-1 signalling through a small molecule.
Human research
The developer reported early phase 1 weight-loss findings. Sponsor announcements are not equivalent to a full independently assessed publication.
Preclinical & other research
Preclinical receptor and metabolic studies informed development.
Safety & unknowns
Early tolerability and limited participant exposure cannot settle long-term safety.
Regulatory status
Investigational; clinical-program status is time-sensitive.
Reported use & evidence
The supplied CT-996 profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.
Sources & references
Follow the cited records and registered research. Profiles remain research drafts.